6月3日，三優生物醫藥（上海）有限公司正式發布了其具有自主產權的三優超萬億創新抗體藥發現平台（STAL）。
三優超萬億創新抗體藥發現平台是由三優生物歷時7年持續創新、自主研發而成，是在三優生物超千億創新抗體發現平台的基礎上取得的重大突破。超萬億創新抗體藥發現平台集成了九種類型的超萬億創新抗體庫，設計庫容高達十萬億；數十個靶點的篩選驗證表明，利用超萬億創新抗體藥發現平台，針對常見靶點可篩選獲得數千個創新型先導分子，先導分子數量是傳統方法的數十乃至數百倍。
眾所周知，全球每年有數億患者受到癌症、自免、過敏和代謝疾病的困擾。單抗藥物、雙抗藥物、ADC藥物、AOC藥物、抗體與核素偶聯藥物、PDC藥物和CAR-T免疫細胞療法等是治療這些重大疾病的主流方法；該類藥物已有100多種獲批上市，已累積造福了數億患者，年銷售額高達近2000億美元；特異性的抗體分子是這些藥物共有的核心元件，發揮着精準靶向的重要作用。
三優超萬億創新抗體藥發現平台無縫銜接了「噬菌體展示」與「哺乳動物細胞蛋白表達」分子產生技術，搭載了全自動化篩選和一體化抗體藥物研發平台，適合挑戰高難創新靶點，也適用於開發高難新型分子；多樣化的抗體庫可匹配「全人抗體、人源化單域抗體、人源化單抗、雙抗、多抗、多肽、ADC、PDC、小型化蛋白」等多種創新大分子藥物的研發需求，所獲分子具有「接近天然、親和力高、可開發性優異」的特點。
三優超萬億創新抗體藥發現平台配備了以客戶需求為中心，模塊化、多樣化和定製化的業務體系，不僅適用於各類創新大分子藥物的研發，還適用於疾病機制研究、診斷產品等的研發。目前，利用三優生物的創新抗體藥發現平台研發的藥物已有數十個項目完成了臨床前候選分子篩選，多個項目完成了臨床前研發並已推進到臨床研發階段。
三優生物CEO郎國竣博士表示：
創新藥物的研發已經逐步步入到了挑戰高難創新靶點、開發高難創新分子、攻關高難度複雜疾病的『三難創新』時代。
三優超萬億創新抗體藥發現平台含有九大超萬億抗體庫，所獲先導分子數量是傳統抗體製備技術的數十到數百倍；該平台集成了全人抗體、人源化抗體、小型化納米抗體、靶向多肽分子和靶向新型蛋白分子等多樣化的大分子藥物產生技術，不僅適用於開發靶向常規表位的抗體，也適用於開發靶向特殊表位、精細化表位的抗體；該平台將噬菌體展示技術和哺乳動物細胞表達技術進行了無縫隙整合，既適合針對人、鼠、猴蛋白等不同物種蛋白的交叉篩選，又適合針對突變位點、競爭分子、Fc融合蛋白、His融合蛋白等差異化蛋白的正負篩選，還適合針對細胞抗原、多肽抗原、膜蛋白抗原等高難度靶點的複雜篩選。
三優超萬億創新抗體藥發現平台與三優生物的創新抗體藥物臨床前一體化平台進行了模塊化的整合，既可靈活的開展各類抗體發現服務、特色技術服務和階段技術服務，又可一站式的完成臨床前候選藥物分子發現和臨床前抗體大分子藥物一體化研發；在該平台的基礎上，三優生物還在並行開展智能化創新抗體藥物發現平台建設。
相信，三優生物的『創新抗體藥物臨床前一體化平台、超萬億創新抗體藥發現平台、智能化創新抗體藥物發現平台』『三駕馬車』並行驅動，將極大的助力廣大合作夥伴突破內卷，從容應對『三難創新』，開發出更加優質的創新藥物，造福廣大病患。
三優生物是一家專注於創新抗體藥物研發和服務的生物高科技企業。公司致力於打造國際領先的創新抗體藥高質量、高通量、集成化研發及價值轉化平台，構建治療、研發和診斷類產品與服務的業務生態系統，協同全球生物製藥、診斷及藥物研發公司，打開人類疾病診斷和治療的新局面。三優生物建立了20000餘平方米、設施設備先進齊全的創新抗體藥物一體化研發實驗室。打造了以系列萬億級噬菌體展示抗體庫為代表的，涵蓋創新抗體藥發現、創新抗體藥優化、生產用細胞株構建、上下游工藝開發、臨床前研發及產業化開發等的40多個核心創新技術平台。構建了「差異化CRO、創新型CPO、特色CRS」於一體的業務體系。公司持續推出「品質最好、速度最快、性價比最高」 （三優）的新技術、新產品、新服務和新場景。公司已和全球300多家製藥公司、藥物研發機構、診斷試劑產品公司建立了友好的業務合作關係。
World Debut | Sanyou Announces Trillion-Level Innovative Antibody Drug Discovery Platform
Sanyou Biopharmaceuticalsofficially launched STAL(Super-Trillion Antibody Libraries)on June3, 2022, which is a super-trillion innovative antibody drug discovery platform of Sanyou’s own intellectual property.
Developed by Sanyou after seven years of continuous innovation and independent R&D, STAL represents asignificantbreakthrough over the previous generation of the sub-trillion innovative antibody discovery platforms. The STAL discovery platform integrates nine categories of super-trillion innovative antibody libraries with the overall library capacity up to 10 trillion. The screening validations with dozens of targets showed that thousands of innovative lead antibodies can be discovered via the STAL platform,and the quantity is dozens or even hundreds of times that of canonical methods.
Hundreds of millions of patients worldwide are suffering from cancer, autoimmune diseases, allergic diseases and metabolic diseases every year. Drugs including monoclonal antibody, bispecific antibody, ADC, AOC, RAC,PDC and CAR-T therapy are the mainstream treatments for these diseases. More than 100 of biological drugs have been approved with total annual market revenue approaching $200 billion.Antibodies with high specificities are the common core components of these drugs and play an important role in precise targeting.
The STAL discovery platform integratestechnologies of phage display and mammalian cell expression, andis supplemented with fully automated screening and integrated antibody drug R&D platforms. The STAL is effective for challenging innovative targets and development of highly difficult drug modalities.It can meet the R&D needs related to the discovery of various innovative biological drugs, including fully human antibodies, humanized single domain antibodies, humanized monoclonal antibodies, bispecific antibodies, multi-specific antibodies, polypeptides, ADC, PDC and miniaturized proteins. The obtained candidates have natural conformations, high affinity and high developability.
The STAL discovery platform is underpinned by a client-oriented, modular, diversified, and customized business system, which is not only applicable to the R&D of various innovative biological drugs, but also to the research of disease mechanisms and development of the diagnostic products.Dozens of projects from the platform have delivered the pre-clinical candidates, several projects have completed the pre-clinical R&D and entered the clinical phase.
Dr. Guojun Lang, CEO of Sanyou said: "the research and development of innovative drugs has gradually entered a challenging era where we to overcome highly difficult innovative targets, novel drug modalities and intriguingly complex diseases ".
"The STAL Discovery Platform comprises nine super-trillion antibody libraries, with the number of lead antibodies up to hundreds of times that of canonical antibody discovery technologies. The platform integrates the generation technologies of a variety of biological drugs such as fully human antibodies, humanized antibodies, miniaturized nanobodies, affinitive polypeptides, and affinitive miniaturized proteins, so that it is suitable not only for developing antibodies targeting conventional epitopes, but also for developing antibodies targeting specific epitopes and refined epitopes. Also, the platform seamlessly integrates phage display technology and mammalian cell expression technology so that it is suitable not only for cross-screening with proteins of different species such as human, mouse, and monkey, but also for positive/negative screening of differentiated proteins such as mutation sites, competing antibodies, Fc fusion proteins and His fusion proteins, as well as for complex screening of difficult targets such as cellular antigens, polypeptide antigens, and transmembrane antigens."
"The STAL Discovery Platform has been modularly integrated with the Pre-Clinical Integrated Innovative Antibody Drug R&D Platform. As a result, various antibody discovery services, featured technical services and staged technical services can be implemented flexibly, and pre-clinical candidate discovery and integrated R&D of pre-clinical biological drugs can be completed as an one-stop solution. On the basis of this platform, Sanyou is also developing an intelligent innovative antibody drug discovery platform."
"It is believed that the Pre-Clinical Integrated Innovative Antibody Drug R&D Platform, the STAL Discovery Platform, and the Intelligent Innovative Antibody Drug Discovery Platform of Sanyou will prominently help our partners to lead the competition, overcome difficulties in drug innovations, and develop more high-quality innovative drugs to benefit the patients."About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a world-leading biotechnology and high-tech enterprise focusing on R&D and services of innovative antibody drugs.
Sanyou is committed to establishing an internationally leading high-quality, high-throughput and integrated R&D and value transformation platform for innovative antibody drugs, constructing a business ecosystem including therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases.
Sanyou has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities. There are 10 major functional modules and more than 40 core technological platforms, which are featured by a series of Super-Trillion phage display antibody libraries and integrated platforms covering innovative antibody drug discovery, innovative antibody drug optimization, production cell line construction, upstream and downstream process development, preclinical R&D and industrial development, etc.
Sanyou has built a business system that integrates "differentiated CRO, innovative CPO and characteristic CRS」, and consistently launches new technologies, new products, new services, and new scenarios base on the principle of high quality, fast delivery and cost-efficiency. Friendly business collaborations have been established with more than 300 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide.
留言列表